### HUMAN CANCER BIOLOGY

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3755</td>
<td>T&lt;sub&gt;H2&lt;/sub&gt; Cytokines from Malignant Cells Suppress T&lt;sub&gt;H1&lt;/sub&gt; Responses and Enforce a Global T&lt;sub&gt;H2&lt;/sub&gt; Bias in Leukemic Cutaneous T-cell Lymphoma</td>
<td>Emmanueulla Guenova, Rei Watanabe, Jessica E. Teague, Jennifer A. Desimone, Ying Jiang, Mitra Dowlatshahi, Christoph Schlaphab, Knut Schuekel, Alain H. Rook, Marianne Tawa, David C. Fisher, Thomas S. Kupper, and Rachael A. Clark</td>
</tr>
<tr>
<td>3764</td>
<td>S100B Promotes Glioma Growth through Chemotraction of Myeloid-Derived Macrophages</td>
<td>Huaqing Wang, Leying Zhang, Ian Y. Zhang, Xuebo Chen, Anna Da Fonseca, Shihua Wu, Hui Ren, Sam Badie, Sam Sadeghi, Mao Ouyang, Charles D. Warden, and Behnam Badie</td>
</tr>
<tr>
<td>3776</td>
<td>Glioma Grade Is Associated with the Accumulation and Activity of Cells Bearing M2 Monocyte Markers</td>
<td>Michael Prosniak, Larry A. Harshyne, David W. Andrews, Lawrence C. Kenyon, Kamil Bedelbaeva, Tatiyana V. Apanasovich, Ellen Heber-Katz, Mark T. Curtis, Paolo Cotzia, and D. Craig Hooper</td>
</tr>
</tbody>
</table>

### CANCER THERAPY: PRECLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3796</td>
<td>Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy</td>
<td>Yi-Xiang Zhang, Jolieke G. van Oosterwijk, Ewa Sicinska, Samuel Moss, Stephen P. Remillard, Tom van Wezel, Claudia Bühnemann, Andrew B. Hassan, George D. Demetri, Judith V.M.G. Boven, and Andrew J. Wagner</td>
</tr>
</tbody>
</table>

See commentary, p. 3719

3820 Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy Emanuela Grassilli, Robert Narloch, Elena Federzoni, Leonarda Ianzano, Fabio Pisano, Roberto Giovannoni, Gabriele Romano, Laura Masiero, Giorgio Stanta, Kristian Helin, and Marialuisa Lavitrano

3832 Leukemia Cell-Rhabdovirus Vaccine: Personalized Immunotherapy for Acute Lymphoblastic Leukemia David P. Conrad, Jovian Tsang, Meaghan Maclean, Jean-Simon Dall’O, Fabrice Le Boeuf, Chantal G. Lemay, Theresa J. Falls, Kelley A. Parato, John C. Bell, and Harold L. Atkins

3844 Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16×33 Bispecific Killer Cell Engager and ADAM17 Inhibition Andres Wiernik, Bree Foley, Bin Zhang, Michael R. Verteris, Erica Warlick, Michelle K. Gleason, Julie A. Boss, Xianghua Luo, Daniel J. Weisdorf, Bruce Walcheck, Daniel A. Vallera, and Jeffrey S. Miller

3856 Therapeutic Potential of HSP90 Inhibition for Neurofibromatosis Type 2 Karo Tanaka, Ascia Esken, Fabrice Chareyre, Walter J. Jessen, Jan Manent, Michiko Niwa-Kawakita, Ruihong Chen, Cory H. White, Jeremie Vitte, Zahara M. Jaffer, Stanley F. Nelson, Allan E. Rubenstein, and Marco Giovannini

3871 Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts Rebecca Volkant, Paola Secchiero, Barbara Ruoci, Flavio Forni, Chiara Agostinis, Lorenzo Caruso, Maria Angela Vandelli, and Giorgio Zauli

3881 Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway Lana McClements, Anita Yakkundi, Angelos Papaspyropoulos, Hannah Harrison, Matthew P. Ablett, Puthen V. Jithesh, Hayley D. McKee, Rachel Bennett, Christopher Donley, Adrien Kissenspennig, Stuart McIntosh, Helen O. McCarthy, Eric O’Neill, Robert B. Clarke, and Tracy Robinson

3894 USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer Sanguine Byun, Sung-Young Lee, Jihoon Lee, Chul-Ho Jeong, Lee Farrand, Semli Lim, Kanamata Reddy, Ji Young Kim, Mee-Hyun Lee, Hyong-Joo Lee, Ann M. Bode, Ki Won Lee, and Ziegang Dong


3914 Temporal and Spatial Evolution of Therapy-Induced Tumor Apoptosis Detected by Caspase-3–Selective Molecular Imaging Quang-Dé Nguyen, Ioannis Lavdas, James Rubbins, Graham Smith, Robin Fortt, Laurence S. Carroll, Martin A. Graham, and Eric O. Abogaye


IMAGING, DIAGNOSIS, PROGNOSIS
Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma

Wen-Wei Zhu, Jia-Jian Guo, Lei Guo, Hu-Liang Jia, Ming Zhu, Ju-Bo Zhang, Christopher A. Loffredo, Marushona Forges, Hua Huang, Xu-Jian Xing, Ning Ren, Qiong-Zhu Dong, Hai-Jun Zhou, Zheng-Gang Ren, Nai-Qing Zhao, Xin Wei Wang, Zhao-You Tang, Lun-Xiu Qin, and Qing-Hai Ye

The Prognostic Value of MicroRNAs Varies with Patient Race/Ethnicity and Stage of Colorectal Cancer

Liselle C. Bovell, Chandrakumar Shanmugam, Balananda-Dhurjati K. Putcha, Venkat R. Katkoori, Bin Zhang, Sejong Bae, Karan P. Singh, William E. Grizzle, and Upender Manne

CANCER THERAPY: CLINICAL

Antibiotic Treatment Decreases Microbial Burden Associated with Pseudomyxoma Peritonei and Affects β-Catenin Distribution

Cristina Semino-Mora, Traci L. Testerman, Hui Liu, Jeannette M. Whitmire, Kimberly Studeman, Yali Jia, Thomas J. McAvoy, Jennifer Francis, Carol Nieroda, Armando Sardi, D. Scott Merrell, and Andre Dubois

Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma

Yan Feng, Amit Roy, Eric Masson, Tai-Tsang Chen, Rachel Humphrey, and Jeffrey S. Weber

Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens

Kimmie Ng, Josep Tabernero, Jimmy Hwang, Emilio Bajetta, Sunil Sharma, Salvatore A. Del Prete, Edward R. Arrowsmith, David P. Ryan, Michaela Sedova, Jin Jin, Kamel Malek, and Charles S. Fuchs

Phase I Dose-Escalation Study of VB-111, an Antiangiogenic Virotherapy, in Patients with Advanced Solid Tumors


Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer

Vered Stearns, Lisa K. Jacobs, Marylo Fackler, Theodore N. Tsangaris, Michelle A. Rudyk, Michaela Higgins, Julie Lange, Zandra Cheng, Shannon A. Slater, Stacie C. Jeter, Penny Powers, Susanne Brist, Calvin Chao, Carl Yoshizawa, Elizabeth Sugar, Igor Espinoza-Delgado, Saraswati Sukumar, Edward Gabrielson, and Nancy E. Davidson

LETTER TO THE EDITOR

PD-L1 Expression in B-cell Lymphomas and Virus-Associated Malignancies—Letter

Mads Hald Andersen

CORRECTION

Correction: Concomitant BRAF and PI3K/mTOR Blockade is Required for Effective Treatment of BRAFV600E Colorectal Cancer

For more information please visit www.aacrjournals.org
ABOUT THE COVER

β-catenin is a transmembrane protein that associates with junctional proteins and assists with the maintenance of cell attachment. As revealed through immunofluorescent staining, β-catenin (shown in green) localizes to the cell membranes and within the lateral junctional complex in normal appendix tissue. In contrast, tissue samples from patients with pseudomyxoma peritonei display primarily cytoplasmic staining of β-catenin and virtually no staining at the intercellular boundaries. However, antibiotic treatment of patients with pseudomyxoma peritonei results in a significant increase in β-catenin within the cell membranes, appearing to aid in the renormalization of β-catenin distribution. For details, see the article by Semino-Mora and colleagues on page 3966 of this issue.
Clinical Cancer Research

19 (14)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/19/14

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pub@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.